A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Year: 2022
Type: article
Source: Blood
Authors: Joshua F. Zeidner, Matthew C. Foster, Mary Johnson, Ying Huang, Ronan T. Swords, Eytan Stein, James M. Foran, Maria R. Baer, Wendy Stock, Yazan F. Madanat, Tibor Kovacsovics, Rebecca L. Olin, William G. Blum, Gary J. Schiller, Tara L. Lin, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, Uma Borate, John C. Byrd, Alice S. Mims
Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Blood Cancer United, The Ohio State University, Oregon Health & Science University, Memorial Sloan Kettering Cancer Center, Mayo Clinic in Florida, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, The University of Texas Southwestern Medical Center, University of Utah, Huntsman Cancer Institute, University of California, San Francisco, Winship Cancer Institute, University of California, Los Angeles, University of Kansas, UPMC Health System, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, UF Health Shands Hospital, University of Florida, University of Cincinnati, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310104966